# Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

> **NCT00394589** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 43 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Infliximab Increased Frequency
- **DRUG:** Infliximab Increased Dose
- **DRUG:** Infliximab Control

## Key facts

- **NCT ID:** NCT00394589
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Study enrollment was stopped due to insufficient subject accrual.
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394589, "Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00394589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*